Vigabatrin: longterm follow-up of electrophysiology and visual field examinations

Acta Ophthalmol Scand. 2003 Oct;81(5):459-65. doi: 10.1034/j.1600-0420.2003.00085.x.

Abstract

Background: To report the results of repeated electrophysiological and visual field examinations in patients with vigabatrin-associated visual field loss (VGB-VFL) and the relationship between these electrophysiological findings, the cumulative dose of vigabatrin and the extent of visual field loss.

Methods: Twenty-two eyes of 11 patients with VGB-VFL were studied. All patients underwent surgery for therapy-resistant epilepsy. Repeated electro-oculograms (EOGs) and flash electroretinograms (ERGs) were made and the cumulative dose of vigabatrin and the visual field loss were recorded after a period of 37-47 months.

Results: The visual field loss was stable in patients who had stopped vigabatrin at the time of the first examination. There was a slight increase in VFL in patients who continued vigabatrin. During the second EOG and ERG, abnormalities in scotopic and photopic a-wave latencies and in scotopic b-wave amplitude were found in more than 50% of patients. Only b-wave latency became normal, while EOG, a-wave latency, a-wave amplitude and b-wave amplitude stayed abnormal. The amount of VFL and the cumulative dose of vigabatrin were statistically correlated with the b-wave amplitude, mainly photopic, found during the first and second examinations.

Conclusion: After 4 years, EOG, flash ERG and visual field loss had not improved in patients with VGB-VFL. The statistically significant correlation found during the first examination between the amount of VFL and the cumulative dose of vigabatrin with the (mainly photopic) b-wave amplitude remained constant.

MeSH terms

  • Adult
  • Anticonvulsants / administration & dosage
  • Anticonvulsants / adverse effects*
  • Dose-Response Relationship, Drug
  • Electrooculography
  • Electroretinography
  • Epilepsy / drug therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Reaction Time
  • Vigabatrin / administration & dosage
  • Vigabatrin / adverse effects*
  • Vision Disorders / chemically induced*
  • Vision Disorders / physiopathology*
  • Visual Fields*

Substances

  • Anticonvulsants
  • Vigabatrin